ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 61 filers reported holding ADC THERAPEUTICS SA in Q2 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $10,847,831 | -22.8% | 2,824,956 | -3.1% | 0.01% | -28.6% |
| Q3 2022 | $14,051,000 | -40.3% | 2,915,160 | -1.6% | 0.01% | -36.4% |
| Q2 2022 | $23,545,000 | -45.8% | 2,961,624 | +0.2% | 0.01% | -35.3% |
| Q1 2022 | $43,439,000 | -23.4% | 2,957,056 | +5.3% | 0.02% | -15.0% |
| Q4 2021 | $56,716,000 | -21.3% | 2,807,723 | +5.8% | 0.02% | -28.6% |
| Q3 2021 | $72,089,000 | -3.0% | 2,654,217 | -13.1% | 0.03% | -6.7% |
| Q2 2021 | $74,347,000 | +15.8% | 3,053,248 | +16.1% | 0.03% | +7.1% |
| Q1 2021 | $64,210,000 | +11.4% | 2,630,491 | +46.1% | 0.03% | +3.7% |
| Q4 2020 | $57,642,000 | +34.6% | 1,800,736 | +38.7% | 0.03% | +17.4% |
| Q3 2020 | $42,840,000 | -1.3% | 1,298,565 | +40.0% | 0.02% | -11.5% |
| Q2 2020 | $43,420,000 | – | 927,577 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,186,215 | $5,718,000 | 3.34% |
| Blue Owl Capital Holdings LP | 733,568 | $3,536,000 | 1.53% |
| Redmile Group, LLC | 7,512,029 | $36,208,000 | 1.40% |
| GCM Grosvenor Holdings, LLC | 735,471 | $3,545,000 | 0.84% |
| Prosight Management, LP | 247,630 | $1,194,000 | 0.64% |
| Indie Asset Partners, LLC | 93,839 | $452,000 | 0.46% |
| MPM BioImpact LLC | 334,384 | $1,612,000 | 0.38% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,390,297 | $11,521,000 | 0.23% |
| Eventide Asset Management | 1,879,959 | $9,061,000 | 0.18% |
| APOGEM CAPITAL LLC | 17,405 | $84,000 | 0.08% |